Beihai Gofar Chuanshan Biological Co. Ltd. Class A

Beihai Gofar Chuanshan Biological Co. Ltd. Class A

SSSE:600538
4.26
CNY
-0.16
(-3.62%)
-0.16EPS
2.51BMarket Cap
Beihai Gofar Chuanshan Biological Co. Ltd. Class A
SSE:600538
(Shanghai Stock Exchange)

Recent

price

4.26

P/E

ratio

- -

div

yld

0.02%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.33
1.9
1.93
1.69
1.1
1.25
1
0.98
0.52
0.52
0.84
0.81
0.92
0.72
0.65
0.64
0.6
Revenue per Share
0.06
-0.14
-0.39
0.04
-0.13
0.01
-0.07
0.02
-0.05
0.01
0.01
0.02
0.07
-0.16
-0.18
-0.17
-0.16
Basic EPS, GAAP
-0.1
-0.1
-0.16
-0.1
-0.25
-0.08
-0.07
0.05
-0.14
-0.02
0.08
-0.06
-0.05
-0.05
-0.02
-0.04
- -
Free Cash Flow per Basic Share
0.08
0.06
0.01
0.02
0.03
0.01
- -
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.63
0.49
0.1
0.16
1.46
1.47
1.4
1.42
1.37
1.39
1.65
1.75
1.82
1.66
1.48
1.31
1.25
Book Value per Share
0.39
0.25
-0.13
-0.04
1.34
1.36
1.29
1.35
1.3
1.32
1.09
1.21
1.28
1.23
1.16
1.12
1.06
Tangible Book Value per Share
273
279
281
267
378
405
455
443
432
481
320
524
498
514
521
515
582
Basic Weighted Avg Shares
363
529
543
452
415
506
455
434
225
251
268
425
460
369
340
328
347
Sales/Revenue/Turnover
-11.28
-2.7
-3.78
-2.14
-10.34
0.84
-10.59
-2.47
-11.62
-4
1.94
3.81
7.06
-3.79
-3
-7.05
-4.46
Operating Margin (%)
37
25
27
22
24
25
26
27
14
15
11
16
16
16
18
18
- -
Depreciation Expense
16
-39
-110
11
-49
4
-32
9
-22
6
3
10
35
-82
-94
-88
-91
Net Income, GAAP
0.92
- -
- -
16.75
- -
14.18
- -
38.65
- -
44.55
66.56
37.13
12.97
- -
- -
- -
- -
Effective Tax Rate (%)
4.52
-7.38
-20.18
2.36
-11.84
0.8
-7
2.04
-9.63
2.3
1.2
2.47
7.58
-22.3
-27.57
-26.69
-26.34
Profit Margin (%)
-238
-257
-272
-273
345
355
320
459
402
358
292
351
365
351
349
362
364
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
4
3
3
6
35
51
64
LT Debt
225
192
92
112
730
738
689
659
638
646
852
923
960
879
787
701
666
Total Equity
-13.38
- -
- -
-25.82
- -
0.89
- -
0.46
- -
0.98
0.49
1.28
4.33
- -
- -
- -
- -
Return on Invested Capital (%)
10.04
- -
- -
9.59
- -
0.4
- -
2.8
- -
0.91
0.43
1.27
3.52
- -
- -
- -
- -
Return on Capital (%)
9.73
-24.83
-132.12
29.43
-13.62
0.6
-4.78
1.35
-3.33
0.9
0.43
1.19
3.73
-9.04
-11.41
-11.98
-12.79
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
4
4
4
LT Borrowings
20
35
35
LT Finance Leases
31
30
29
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
524
524
524
Market Capitalization
3,512
3,177
2,511

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
495
502
497
Cash, Cash Equivalents & STI
123
137
100
Accounts Receivable, Net
158
150
157
Inventories
86
87
86
Total Current Liabilities
128
121
133
Payables & Accruals
- -
- -
- -
ST Debt
4
4
4
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.15%
-3.49%
-11%
Free Cash Flow
-114.15%
-28.89%
144.55%
Net Income, GAAP
-139.83%
26.21%
-6.64%
Sales/Revenue/Turnover
-0.87%
7.17%
-3.59%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
88
89
87
77
340
2025
79
75
- -
89
328
2026
83
77
98
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.01
-0.01
-0.14
-0.18
2025
0.01
-0.02
- -
-0.16
-0.17
2026
-0.01
-0.01
0.01
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Beihai Gofar Chuanshan Biological Co., Ltd. (600538.SS) is a China-based company primarily engaged in the production, distribution, and sale of pharmaceutical products, pesticides, and related medical services. The company offers a range of proprietary Chinese medicines and medical devices, including Haibao pearl eye drops, pearl powder, nacre powder, Guofa brand Weichangning gastroenteric granules, honeysuckle mixture, fertilizer syrup, Haima brand herbal medicines, sea snake medicinal liquor, and ethanol disinfectants; it also provides molecular diagnostics, nucleic acid extraction systems such as silicon-magnetic integrated DNA quantitative extraction workstations and automatic microDNA extraction workstations, judicial IVD services, molecular medical imaging centers, tumor radiotherapy centers, and tumor telemedicine technical services. Operations span pharmaceutical manufacturing, pharmaceutical distribution, deoxyribonucleic acid identification and services, and other segments, with a focus on domestic markets in China and subsidiaries primarily in Guangxi and Hunan provinces. Founded in 1993 and headquartered at No. 3, Beibuwan Middle Road, Haicheng District, Beihai City, Guangxi Zhuang Autonomous Region, the company leverages marine resources from the Beibu Gulf for biopharmaceuticals, biopesticides, and seaweed liquid fertilizers. In June 2021, the company changed its Chinese name from Beihai Guofa Marine Biotechnology Co., Ltd. to Beihai Guofa Chuanshan Biological Co., Ltd., reflecting its emphasis on biological products; more recently, in 2025, Chairman Jiang Ye completed a shareholding increase of approximately 4.8 million shares valued at RMB 30 million through centralized bidding on the Shanghai Stock Exchange, signaling strengthened insider confidence amid ongoing operations in the pharmaceutical and biotech sectors.